

# CURRICULUM VITAE – Sangeeta Sule, M.D.

---

Sangeeta Sule, M.D.

January 7, 2009  
Date of Version

## **I. DEMOGRAPHIC INFORMATION**

### **I. Current Appointment**

Assistant Professor, Pediatrics

Joint Appointment, Department of Medicine, Johns Hopkins University School of Medicine

200 North Wolfe Street  
Suite 2-126  
Baltimore, MD 21205  
Telephone: 410-955-6145  
Fax: 410-614-9773  
E-mail: ssule@jhmi.edu

### **II. Personal Data**

**Full Name:** Sangeeta Dileep Sule

**Business address:** Johns Hopkins University School of Medicine  
Division of Pediatric Nephrology  
200 North Wolfe Street  
Suite 2-126  
Baltimore, MD 21205

### **III. Education and Professional Training**

1989-1992	Tulane University New Orleans, Louisiana	B.S. Cellular and Molecular Biology
1992-1996	Baylor College of Medicine Houston, Texas	M.D.
1996-2000	Baylor College of Medicine Houston, Texas	Intern & Resident Internal Medicine and Pediatrics
2000-2003	Johns Hopkins University Baltimore, Maryland	Clinical and Research Fellow Rheumatology
2001-2008	Johns Hopkins University School of Hygiene and Public Health Baltimore, Maryland	Ph.D. Clinical Investigation

## IV. Professional Experience

2003-2004	Johns Hopkins University Baltimore, MD	Instructor of Pediatrics Pediatric Rheumatology Division of Pediatric Immunology
2004-2006	Johns Hopkins University Baltimore, MD	Assistant Professor of Pediatrics Pediatric Rheumatology Division of Pediatric Immunology
2006	Johns Hopkins University Baltimore, MD	Assistant Professor of Pediatrics Pediatric Rheumatology Division of Pediatric Nephrology

## II. RESEARCH ACTIVITIES

### I. Peer-Reviewed Publications

1. Sule SD, Wigley FM. Update on Management of Scleroderma. *Bull Rheum Dis.* 49:1-4; 2000.
2. Sule SD, Bathon JM. Disease-Modifying Effects of New Rheumatoid Arthritis Therapies. *Resid Staff Physician.* 47:15-27; 2001.
3. Wigley FM, Sule SD. Novel Therapy in the Treatment of Scleroderma. *Expert Opin Investig Drugs.* 10:31-48; 2001.
4. Sule SD, Wigley FM. Treatment of Scleroderma: an Update. *Expert Opin Investig Drugs.* 12:471-482; 2003.
5. Sule SD, Bartlett S, Parker A, Dorsi M, Towns M, Bathon JM. Preoperative Autologous Blood Donation by Arthritis Patients is Associated with Preoperative Anemia and Perioperative Transfusion. *Journal of Clinical Rheumatology.* 10:252-258; 2004.
6. Sule SD, Petri M. Socioeconomic Status in SLE. *Lupus.* 15:720-723; 2006.
7. Sule SD, Fadrowski J, Fivush B, Gorman G, Furth S. Reduced Albumin Levels and Utilization of Arteriovenous Access in Pediatric Patients with SLE. *Pediatric Nephrology.* 22:2041-2046; 2007.

8. Chung L, Shaprio L, Fiorentino D, Baron M, Shanahan J, Sule SD, Hsu V, Rothfield N, Steen V, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahalh B, Csuka ME, Gruber B, Collier D, Sweiss N, Matthews E, Gilbert A, Dechow F, Gregory J, Wigley FM. MQX-503, A Novel Topical Nitroglycerin Formulation, Improves Severity of Raynaud Phenomenon in a Heterogeneous Patient Population. Accepted for publication *Arthritis & Rheumatism*. Nov 2008
9. Sule SD, Rosen A, Petri M, Andrade F. Abnormal Production of Pro-and Anti-inflammatory Cytokines in Response to Apoptotic Cells is an Intrinsic Property of Lupus Monocytes. Submitted to *Arthritis & Rheumatism*. Dec 2008.
10. Tincopa M, Gerstenblith M, Puttgen K, Sule SD, Cohen B. Bullous Lupus: An Unusual Initial Presentation of Systemic Lupus Erythematosus in an Adolescent Girl. Submitted to *Pediatric Dermatology*. Jan 2009
11. Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Persistence of Hypoalbuminemia and Temporary Vascular Access in Pediatric Patients with Systemic Lupus Erythematosus Receiving Adequate Hemodialysis. Submitted to *Pediatric Nephrology*. Jan 2009.

### **Peer-Reviewed Manuscripts in Preparation**

1. Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Mortality in Pediatric Patients with Systemic Lupus Erythematosus Receiving Adequate Hemodialysis.
2. Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Comparison of Mortality between Pediatric and Adult Patients with Systemic Lupus Erythematosus Maintained on Hemodialysis.
3. Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Hospitalization Rates in Pediatric Patients with Systemic Lupus Erythematosus Receiving Adequate Hemodialysis.
4. Sule SD, Fivush B, Furth S. Clinical Characterization of the Johns Hopkins Pediatric SLE Cohort

## **II. Book Chapters**

1. Sule SD, Bathon JM. Etanercept. In: Moreland LM, Emery P. TNF Inhibition in the Treatment of Rheumatoid Arthritis, 1<sup>st</sup> Edition. London: Martin Dunitz, 2003.
2. Sule SD, Wigley FM. Raynaud's Phenomenon.. In: Imboden J, Hellmann D, Stone J. ed. Current Diagnosis & Treatment of Rheumatic Diseases, 1<sup>st</sup> Edition. New York: Lange Medical Books/McGraw-Hill, 2004.

3. Sule SD, Wigley FM. Raynaud's Phenomenon. In: Current Diagnosis & Treatment of Rheumatic Diseases, 2<sup>nd</sup> Edition. Lange Medical Books/McGraw-Hill, 2006.
4. Sule SD, Petri M. Nutrition in SLE. In: Nutrition and Autoimmune Diseases, Humana Press, 2006.
5. Sule SD. Juvenile Rheumatoid Arthritis and SLE. Clinical Care in the Rheumatic Diseases, 1<sup>st</sup> Edition, 2006.
6. Sule SD, Petri M. Estrogen in SLE. Endocrine Manifestations of Systemic Autoimmune Diseases ; Handbook of Systemic Autoimmune Diseases, Volume 9, 2008.

### **III. Abstracts (\*presented)**

- 1.\* Sule SD, Wise RA, Orens JB, Wigley FM. Higher Pulmonary Artery Pressures in Scleroderma Compared to Idiopathic Pulmonary Fibrosis. *Arthritis Rheum.* 48 (Suppl. 9) S556; 2002.
- 2.\* Sule SD, Hummers LK, Lima J, Wise RA, White B, Wigley FM. Are Doppler Echocardiograms Useful in the Evaluation of Scleroderma Patients? *Arthritis Rheum.* 48 (Suppl. 9) S558; 2003.
- 3.\* Sule SD, Hummers LK, Wigley FM. A Longitudinal Study of Estimated Right Ventricular Systolic Pressure (RVSP) by Doppler Echocardiography (ECHO) as a Predictor of Mortality in Systemic Sclerosis (Scleroderma). *Arthritis Rheum.* 50(Suppl. 9) S421; 2004.
- 4.\* Hameed S, Magder L, Rosen A, Petri M, Sule SD. Monocyte Cytokine Secretion in Systemic Lupus Erythematosus: Relevance to Clinical Disease Activity. *Arthritis Rheum.* 51(Suppl. 9) S422; 2006.
- 5.\* Sule SD, Rosen A, Wigley F. Characterization of Transforming Growth Factor (TGF)- $\beta$  Secretion from Monocytes in Systemic Sclerosis. *Arthritis Rheum.* 51(Suppl. 9) S526; 2006.
6. Sule SD, Gorman G, Fivush B, Furth S. Differences in Clinical Characteristics between Pediatric HD Patients with SLE and Patients with ESRD on HD Secondary to Other Causes. *JASN.* 17(abstract issue) 885A; 2006.
- 7.\* Sule SD, Gorman G, Fivush B, Furth S. Achievement of Clinical Targets in Pediatric Systemic Lupus Erythematosus (SLE) Patients on Hemodialysis (HD). *JASN.* 17(abstract issue) 426A; 2006.

8. \* Sule SD, Fadrowski J, Fivush B, Gorman G, Furth S. Achievement of Clinical Targets Over Time in Pediatric Systemic Lupus Erythematosus (SLE) Patients with End Stage Renal Disease (ESRD) on Hemodialysis (HD). Poster presentation at PAS Meeting, Toronto, Canada. 2007.
9. \* Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Increased Mortality Risk Associated with Systemic Lupus Erythematosus (SLE) in Pediatric vs. Adult ESRD Patients. *JASN*. 18(abstract issue) 612A; 2007 and *Arthritis Rheum* 58(supplement 9) 227; 2008.
10. \* Sule SD, Fadrowski J, Fivush B, Neu A, Furth S. Mortality in Pediatric Patients with ESRD secondary to Systemic Lupus Erythematosus (SLE). *JASN*. 18(abstract issue) 613A; 2007 and *Arthritis Rheum* 58(supplement 9) 226; 2008.
11. \* Sule SD, Hummers L, Shapiro L, Fiorentino D, Chung L, Baron M, Shanahan J, Hsu V, Rothfield N, Steen V, Martin R, Dugowson C, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Klaff L, Dechow F, Gregory J, Wigley F. Safety and tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud's phenomenon. *Arthritis Rheum* 57(supplement 9) 227; 2007.
12. \* Belch, J, Fiorentino D, Denton C, Herrick A, Sule SD, Steen V, Rothfield N, Scheja A, Shapiro L, Shanahan J, Emery P, Chung L, Gregory J. MQX-503, a Novel Topical Nitroglycerin Formulation, Improves Severity of Symptoms Associated with Raynaud's Phenomenon. *Arthritis Rheum* 58(supplement 9) 1220; 2008.
13. \* Hsu V, Shapiro L, Fiorentino D, Rothfield N, Steen V, Martin R, Smith E, Sule SD, Csuka ME, Mayes M, Kahaleh B, Gruber B, Simms R, Sweiss N, Dechow F, Gregory J, Wigley FM. Phase III Open-Label Study of Topical Nitroglycerin, MQX-503, in the Treatment and Prevention of Raynaud's Phenomenon. *Arthritis Rheum* 58(supplement 9) 1773; 2008.
14. \* Rothfield, N, Shapiro L, Fiorentino D, Chung L, Denton C, Herrick A, Baron M, Shanahan J, Hsu V, Belch J, Steen V, Scheja A, Martin R, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Sule SD, Emery P, Wigley FM. Safety and Tolerability of MQX-503, a Novel Investigational Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon. *Arthritis Rheum* 58(supplement 9) 1774; 2008.
15. \* Herrick A, Denton C, Fiorentino D, Sule SD, Rothfield N, Belch J, Shapiro L, Scheja A, Shanahan J, Steen V, Chung L, Emery P, Wigley FM, Gregory J. Comparison of Responders and Non-Responders to MQX-503, a Novel Investigational Topical Nitroglycerin Formulation, in Treatment of Scleroderma-Related and Non-Scleroderma Related Raynaud's Phenomenon. *Arthritis Rheum* 58(supplement 9) 1778; 2008.

#### **IV. Research Support**

6/2003-6/2006	Arthritis Foundation Physician Scientist Development Award “Autoimmune Mechanisms in Chronic Granulomatous Disease” \$50,000/year Principal Investigator 55% effort
1/2005-12/2005	Johns Hopkins Clinician Scientist Award "Cohort Study of Pediatric SLE" \$48,872 Principal Investigator 25% effort
1/2006-12/2006	Johns Hopkins Clinician Scientist Award “Cohort Study of Pediatric SLE” \$69,375 Principal Investigator 75% effort
8/2006-8/2007	Rheumatic Disease Research Core Center NIH/NIAMS “Apoptotic cell clearance and resulting cytokine secretion in pediatric SLE” \$91,532 Co-investigator 10% effort
1/2007-5/2007	Mediquest Therapeutics, Inc. Phase III, In-Life Study of Topical Nitroglycerin, Cross-Over Study \$25,000 for study initiation \$10,000 per patient
1/2007-5/2007	Mediquest Therapeutics, Inc. Open-Label Study of Topical Nitroglycerin \$1750 per patient
7/2007-6/2008	National Kidney Foundation Mini-Grant Award “Comparison of Mortality between Pediatric and Adult Patients with SLE” \$7,500 Principal Investigator
7/2008-6/2012	NIH/NIAMS K23 grant application “Cohort Study of Pediatric SLE” \$125,500/year for 5 years Principal Investigator 75% effort

### **III. EDUCATIONAL ACTIVITIES**

#### **I. Teaching**

##### **Classroom Instruction**

- 2004-present “Juvenile Rheumatoid Arthritis” Lecture to Internal Medicine Residents every 3 months
- 2004-present “SLE” Lecture to Pediatric House Staff yearly
- 2005-present “Reasons for Pediatric Rheumatology Referral” Lecture to Pediatric House Staff
- 2005 Small group discussion leader for pathophysiology course for 2<sup>nd</sup> year medical students
- 2006-present Lectures to Pediatric House Staff on Renal Elective every 2 months
- 2006-present Lectures to Pediatric Renal Fellows in the Pediatric Nephrology core lecture series every 2 months

##### **Clinical Instruction**

- 2004 -present Outpatient Rheumatology Clinic twice a week  
Attending Physician-Supervision of Pediatric Residents rotating on elective
- 2004-present Inpatient Rheumatology ward consultant 50% of year

#### **II. CME Instruction**

- 2002 The European League Against Rheumatism Meeting  
Berlin, Germany  
“Raynaud’s Phenomenon”
- 2005 Pediatric Grand Rounds  
St. Agnes Medical Center  
Baltimore, Maryland  
“Pediatric SLE”
- 2005 Pediatric Grand Rounds  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Pediatric SLE: Insights into Pathogenesis”

- 2006 33<sup>rd</sup> Annual Pediatric Trends  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Pediatric SLE”
- 2006 American Society of Pediatric Nephrology Meeting  
San Francisco, California  
“Rituximab in Pediatric SLE”
- 2007 2<sup>nd</sup> Annual Advances in the Diagnosis and Treatment of Autoimmune Rheumatic  
Diseases CME Course  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Juvenile Rheumatoid Arthritis: Advances in the Diagnosis and Treatment of the  
Rheumatic Diseases”
- 2007 34<sup>th</sup> Annual Pediatric Trends  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Commonly Used Treatments in Rheumatologic Disorders”
- 2007 Adolescent Grand Rounds  
Johns Hopkins University  
Baltimore, Maryland  
“Pediatric SLE”
- 2008 Pediatric Grand Rounds  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Clinical Outcomes in Pediatric Patients with SLE”
- 2008 35<sup>th</sup> Annual Pediatric Trends  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Pediatric Rheumatology for the Clinician”

### **III. Advisory Group**

- 2005 NIH Study Section Member  
Pediatric RO1 Grant Review Session  
Bethesda, Maryland



## **IV. CLINICAL ACTIVITIES**

### **I. Board Certifications**

2000, recertified 2007 American Board of Pediatrics

2000 American Board of Internal Medicine

2003 American Board of Internal Medicine, Sub-board of Rheumatology

## **V. ORGANIZATIONAL ACTIVITIES**

### Department of Pediatrics

2007 Active Internship Application Participant  
Interviewed applicants for pediatric residency training

### Division of Nephrology

2006 Active Advocacy Committee  
Participated in advocacy program Camp All-Stars

2006 Active Pediatric Rheumatology Lecture Series  
Coordinated educational series lectures for pediatric residents and pediatric renal fellows

## **VI. RECOGNITION**

### **I. Honors and Awards**

1989 Deans Honors Scholarship  
Tulane University

1992 Honors Thesis  
Tulane University

1992 Outstanding Senior in Clinical & Molecular Biology  
Tulane University

1992 Summa cum Laude  
Tulane University

1992 Phi Beta Kappa  
Tulane University

- 2001 Graduate Training Program in Clinical Investigation Tuition Award.  
Jointly Administered by the Johns Hopkins School of Hygiene and Public Health  
And School of Medicine
- 2001 Arthritis Foundation Engalitcheff Fellowship Award
- 2001 Arthur B. Modell Postdoctoral Fellowship Award
- 2006 Graduate Training Program in Clinical Investigation  
Preliminary Oral Examination Completed
- 2007 National Kidney Foundation Mini-Grant Award Recipient
- 2008 Graduate Training Program in Clinical Investigation  
Ph.D. Thesis Accepted

## **II. Selected Invited Talks**

- 2000 3<sup>rd</sup> Interdisciplinary Symposium on the Treatment of Autoimmune Disorders  
Leipzig, Germany  
“Treatment of Scleroderma”
- 2001 Arthritis Foundation Meeting  
Baltimore, Maryland  
“Chronic Granulomatous Disease and Autoimmunity
- 2002 European League Against Rheumatism Meeting  
Berlin, Germany  
“Raynaud’s Phenomenon”
- 2006 American Society of Pediatric Nephrology Meeting  
San Francisco, California  
“Rituximab in Pediatric SLE”
- 2006 Johns Hopkins International Vasculitis Symposium  
Baltimore, Maryland  
“Pediatric Vasculitis”
- 2007 Johns Hopkins Dermatology Grand Rounds  
Baltimore, Maryland  
“Pediatric SLE”
- 2007 2<sup>nd</sup> Annual Advances in the Diagnosis and Treatment of Autoimmune Rheumatic  
Diseases CME Course  
Johns Hopkins University School of Medicine  
Baltimore, Maryland

“Juvenile Rheumatoid Arthritis: Advances in the Diagnosis and Treatment of the Rheumatic Diseases”

- 2007 Johns Hopkins Adolescent Grand Rounds  
Baltimore, Maryland  
“Pediatric SLE”
- 2008 Pediatric Grand Rounds  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Clinical Outcomes in Pediatric Patients with SLE”
- 2008 35<sup>th</sup> Annual Pediatric Trends  
Johns Hopkins University School of Medicine  
Baltimore, Maryland  
“Pediatric Rheumatology for the Clinician”

### **III. Professional Societies**

- 2000-present American Academy of Pediatrics
- 2000-present American College of Physicians
- 2000-present American College of Rheumatology
- 2001-present Arthritis Foundation
- 2006-present American Society of Nephrology